Privately-held US drug discovery firm Gencia has entered into a partnership with Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502) to develop a new class of small molecule drugs as potential treatments for hematological and inflammatory diseases.
Called mitochondrial agonists of the glucocorticoid receptor (MAGR), such compounds may offer the therapeutic potential of conventional glucocorticoid drugs (steroids). However, MAGR are chemically distinct and may function differently than steroids.
The initial aim of the collaboration will be joint R&D leading to two preclinical drug candidates, one each in the areas of inflammation and oncology. Takeda will explore opportunities to conduct clinical trials for drug candidates identified by the partnership.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze